logo
‘Ravenousness was in my job description.' What happens when a food writer goes on a weight-loss drug?

‘Ravenousness was in my job description.' What happens when a food writer goes on a weight-loss drug?

Boston Globe02-04-2025

But as a food writer, I did wonder: Um, what if I just wasn't hungry anymore? Ravenousness was in my job description. And yet, as a fairly confident person for most of my life, I was tired of feeling self-conscious about my weight all the time, and it finally reached a breaking point two months ago.
Get Winter Soup Club
A six-week series featuring soup recipes and cozy vibes, plus side dishes and toppings, to get us all through the winter.
Enter Email
Sign Up
I should have been giddy. I'd just moderated an author talk at the Harvard Book Store — my own personal Madison Square Garden — before a crowd of women. I asked good questions; I left 'em laughing.
But I also felt like a sack of loose potatoes, angling my body this way and that on a wobbling metallic stool. I chose a formless black dress and sucked in my stomach with all manner of Spanx. When I got home and peeled off my armor, my skin had red indentations. And, when the author and the bookstore shared photos from the event, I winced. I didn't post on Instagram. I didn't tag myself with a perky caption.
Advertisement
I thought: I really used to like how I looked, and I just don't anymore. This has to change, even if my appetite changes with it.
And so I visited my primary care doctor and asked for ideas, knowing that several friends already took similar drugs with good results. He immediately suggested Zepbound. I qualified: At just 5′1, I was about 30 pounds overweight, with a pesky ring of visceral fat around my belly. Beyond that, I have a family history of heart disease. My cholesterol, while not awful, was borderline. My insurance, Blue Cross Blue Shield of Massachusetts, approved coverage right away.
Getting the prescription was the easy part. The challenging part came later: I worried that I was wimping out by not embracing the evolution of my 40-something body, whose metabolism was slowed by perimenopause, hindered by SSRIs (often implicated in weight gain but necessary to manage panic disorder), and the birth of two very large children.
There was an element of feeling like I was letting myself — and all of womanhood — down, by caving to Big Pharma and Big Vanity, not to mention relinquishing a part of my personality.
When my teenager began medication for ADHD, he asked me: Will I still be funny? Now that I was prescribed Zepbound, I wondered: Would I still like to eat? Dim sum brunch was the highlight of any weekend. I threw elaborate dinner parties with friends based on obscure themes. I write about restaurants in this very newspaper, for God's sake.
Advertisement
Who would I be if I didn't love food?
But there was also a more pressing issue: Would I be anyone at all if I continued on this semi-unhealthy trajectory? I come from a long line of people with cardiac problems. Both of my grandmothers were,
ahem
, buxom. But my Nana wore a girdle; now, I had an injector pen. There was a tool that could potentially help me feel better and live healthier. Why struggle without it?
On the advice of a friend, I injected the first vial on a Monday, so I wouldn't ruin my weekend with potential side effects. I shot into my stomach. It didn't hurt; just a slight click and the dose was done. A metallic taste flooded my mouth immediately; a quick Reddit scroll confirmed that this was common. That night, I became nauseated, similar to the first trimester of pregnancy. Vomiting would have been appealing. I didn't eat much dinner, and I belched like a frat boy for a few hours while trying to focus on 'The White Lotus.'
By Tuesday, I was unhungry. It wasn't that I felt sick; eating just wasn't central to my mind-set. The perpetual hum in my mind — when would I snack again? what was for dinner? — evaporated. When my husband suggested salmon and broccoli, I didn't fixate. That was fine. I didn't really care. I ate a small portion; when I was done, I was done. Wednesday was similar: I had a banana and yogurt, and I swapped my morning walk with a friend for coffee at home, just in case I needed a bathroom. At dinner, I had one slender slice of pizza. There was no want. It wasn't until my hunger had vanished that I realized how much space food, and the pursuit of it, occupied in my mind.
Advertisement
I was quite pleased until Friday morning, when I woke up early to go to Pilates. Exercise is also a crucial complement to weight-loss drugs. They aren't a golden ticket to sloth and inactivity. I still have to move, and I still need to eat right, because nutrients are so important if your body isn't naturally cueing you up for hunger.
But my cramping reminded me of the early throes of childbirth. I could hardly sit up straight. Two Gas-X solved the issue, and I forced myself to class — and told my instructor that I'd started a new drug and not to panic if I just laid flat on my reformer. Awesome, she said, as if I told her I was going to Tahiti. I made it through.
By the weekend, I felt completely back to my old self, with one important change: I could regulate my food intake. When we grabbed dinner from Five Guys after my son's late basketball game on Friday night, I had 10 delicious fries, not the whole carton. I slurped half a chocolate shake, not the whole damn thing.
On Sunday, I celebrated a pal's birthday brunch at Foundry on Elm in Somerville. I shared poutine. In the past, I would have mindlessly swiped eggs through gravy until the skillet was dry. Instead, I was pleasantly satiated halfway through. It really was that simple: For the first time in years, I actually felt full.
Advertisement
Now, a few weeks in, my GI woes have resolved, my appetite is modest but present, and I've shed 6 pounds. And here's the thing. I still eat; I just do less of it, more slowly and mindfully. It's like going to the movies: You can appreciate cinema. You can lose yourself in the story. You can relish every frame, but you also know when it's time to leave the theater. You don't need to see the same show four times in a row.
Part of me does think Zepbound is like AI for weight loss, a modern cheat that's almost too easy. I sometimes feel that anything worth doing should be pursued the old-fashioned way — diet, exercise — even if the results don't come because of other medications, genetics, or age.
But most of the time, I'm content with my choice, because the truth is: I'm losing weight on this medication. I feel better, I look better, and the side effects are manageable. I trust my doctor, who assures me that it's safe. Friends who take it feel similarly, and so do the thousands of people I've met on message boards (there are plenty of them!) on a similar journey.
And, most of all, I still love food. I just want to be around as long as possible to enjoy it.
Kara Baskin can be reached at

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Iris Ventures Leads Multimillion-dollar Investment Into Fast-growing Wellness Platform Healf
Iris Ventures Leads Multimillion-dollar Investment Into Fast-growing Wellness Platform Healf

Yahoo

time2 hours ago

  • Yahoo

Iris Ventures Leads Multimillion-dollar Investment Into Fast-growing Wellness Platform Healf

— Healf, a leading online retailer selling premium wellness products, has closed a multimillion-dollar funding round led by Iris Ventures, an international growth equity firm specializing in next-generation lifestyle and health-focused brands. Launched four years ago by brothers Lestat McCree and Max Clarke, Healf has become one of the U.K.'s fastest-growing well-being companies. It has built a reputation for its polished curation, clear communication and a personalized approach to well-being. More from WWD The Top Five Health and Wellness Trends in 2025, According to The Vitamin Shoppe Farfetch Pushes Into South Korea, One of the World's Biggest Luxury Markets EXCLUSIVE: Beekman 1802 Founders Release Book 'G.O.A.T. Wisdom: How to Build a Truly Great Business' The company has been able to scale quickly in what remains a fragmented market in the U.K., populated by pharmacies and retail chains that are often cluttered with product — and the opposite of aspirational. Healf has a growing community of 325,000 customers and 282,000 followers on Instagram, and is on track to post $100 million in revenue by the end of 2025. The plan is to expand Healf across Europe and capitalize on the booming wellness trend. The personal health and well-being category alone is estimated to be worth $1.8 trillion globally. Healf's approach is to help people take control of their health with a holistic approach that's focused on the basics: eating, moving, sleeping and mindfulness. The site stocks more than 4,000 curated products to tend to those needs, and helps customers personalize their approach. Healf is also packed with slick editorial images and articles on how to lower cortisol levels naturally; special massages for lymphatic health; and how to bring 'more brain-soothing beauty into your life.' Customers take surveys to help them target the best remedies, and there is also an AI assistant that doles out recommendations about gut health, sleep habits and how to manage stress and anxiety. McCree said he and Clarke started the company because 'well-being shouldn't feel overwhelming — but it so often does. From Day One, Healf has been dedicated to cutting through the noise with simplicity, credibility and curation.' He added that the company's trademarked Four Pillars strategy focused on eating, moving, sleeping and mindfulness acts as a compass, and helps the founders deliver on quality, service and product offerings. Clarke said he and his brother were inspired by their own well-being journeys and have experienced the 'tangible and synergistic benefits that accompany a holistic approach to well-being — a major unlock we believe all consumers deserve access to.' Florian Wojewodzki, partner at Iris Ventures, said 'we quickly understood that Max and Lestat were a rare breed of founders. They are mission-driven brothers exemplifying laser focus and militant execution at every turn. 'Their uncompromising pursuit of product, innovation and customer journey excellence has been a masterclass, and propelled Healf to the forefront of health and wellness disruption. The company's highly engaged and growing community is a testament to its standout offering and the consumer trust it has so deservedly earned,' Wojewodzki said. Montse Suarez, founder and managing partner of Iris Ventures, said that 'with smart retail curation, personalized tech, and habit-forming products, wellness is no longer an add-on — it's seamlessly woven into everyday life. We're seeing a powerful shift from reactive fixes to proactive strategies. 'Max and Lestat recognized this early on and, with unwavering focus on excellence, have rapidly built an exceptional business. We're proud to partner with them and to help shape the future of well-being together,' she said. Iris Ventures is a thematic fund targeting European, U.K. and U.S. high-growth customer-centric brands and tech-enabled solutions across consumer sectors including beauty, health, wellness, family, lifestyle, nutrition, daily tech and modern commerce. Recent investments have included Maurten, a global sports nutrition company based in Sweden; Biomel, a plant-based gut health brand; and Superlativa, a drug- and hormone-free supplement that aims to help manage stress and regulate women's levels of cortisol. Best of WWD Harvey Nichols Sees Sales Dip, Losses Widen in Year Marred by Closures Nike Logs $1.3 Billion Profit, But Supply Chain Issues Persist Zegna Shares Start Trading on New York Stock Exchange Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs

Yahoo

time5 hours ago

  • Yahoo

Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs

Eli Lilly (NYSE:LLY) lands an $870 million pact with Camurus (CAMX) to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's team will work hand-in-glove with Camurus engineers, adapting the gel-matrix delivery platformalready proven in other therapiesto Lilly's top weight-loss candidates, including Zepbound. Instead of daily or weekly shots, patients could look forward to a monthly injection or even a once-daily pill that behaves like a slow-release depot. The deal kicks off with an upfront payment and scales into development and commercialization milestones, keeping Lilly's risk in check while aligning both firms on successful trial readouts. This move comes as Lilly races against rivals in the booming obesity marketnow set to exceed $50 billion by 2030and follows its own push for an oral GLP-1 option to rival injectables. By offering less-frequent dosing, Lilly hopes to tackle patient drop-off and win market share from peers like Novo Nordisk. Plus, the modified release format could open doors to new payer contracts, since fewer doses often translate to better adherence and lower overall costs. Why It Matters: Extended-release obesity drugs could revolutionize treatment by cutting patient burden and boosting lifetime revenue. Lilly's bet on Camurus' delivery system underscores its commitment to leading the metabolic disease space rather than just competing on molecule potency. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs
Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs

Yahoo

time5 hours ago

  • Yahoo

Eli Lilly Bets $870 Million on Extended-Release Obesity Drugs

Eli Lilly (NYSE:LLY) lands an $870 million pact with Camurus (CAMX) to build long-acting obesity treatments, tapping FluidCrystalslow-release tech to stretch dosing from days to weeks. Lilly's team will work hand-in-glove with Camurus engineers, adapting the gel-matrix delivery platformalready proven in other therapiesto Lilly's top weight-loss candidates, including Zepbound. Instead of daily or weekly shots, patients could look forward to a monthly injection or even a once-daily pill that behaves like a slow-release depot. The deal kicks off with an upfront payment and scales into development and commercialization milestones, keeping Lilly's risk in check while aligning both firms on successful trial readouts. This move comes as Lilly races against rivals in the booming obesity marketnow set to exceed $50 billion by 2030and follows its own push for an oral GLP-1 option to rival injectables. By offering less-frequent dosing, Lilly hopes to tackle patient drop-off and win market share from peers like Novo Nordisk. Plus, the modified release format could open doors to new payer contracts, since fewer doses often translate to better adherence and lower overall costs. Why It Matters: Extended-release obesity drugs could revolutionize treatment by cutting patient burden and boosting lifetime revenue. Lilly's bet on Camurus' delivery system underscores its commitment to leading the metabolic disease space rather than just competing on molecule potency. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store